HIV Risk Reduction and Drug Abuse Treatment in Malaysia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Johor
-
Muar, Johor, Malaysia
- Substance Abuse Research Center
-
-
-
-
Connecticut
-
New Haven, Connecticut, United States, 06519
- Yale University School Of Medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Opioid dependence
Exclusion Criteria:
- Dependence on alcohol, benzodiazepines or sedatives
- Suicide or homicide risk
- Psychotic disorder or major depression
- Inability to read or understand the protocol or assessment questions
- Life-threatening or unstable medical problems
- Greater than 3 times normal liver enzymes (AST, GGT)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
Time to relapse
|
|
Time to resumption of heroin use
|
|
Maximum consecutive weeks of opiate abstinence
|
|
Reduction of HIV risks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
Adverse events
|
|
Addiction-related functional status
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Richard S. Schottenfeld, M.D., Yale University
- Study Director: Mahmud Mazlan, M.D., Hospital Muar, Malaysia
Publications and helpful links
General Publications
- Mazlan M, Schottenfeld RS, Chawarski MC. New challenges and opportunities in managing substance abuse in Malaysia. Drug Alcohol Rev. 2006 Sep;25(5):473-8. doi: 10.1080/09595230600883354.
- Chawarski MC, Mazlan M, Schottenfeld RS. Heroin dependence and HIV infection in Malaysia. Drug Alcohol Depend. 2006 Apr;82 Suppl 1:S39-42. doi: 10.1016/s0376-8716(06)80007-4.
- Schottenfeld RS, Chawarski MC, Mazlan M. Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial. Lancet. 2008 Jun 28;371(9631):2192-200. doi: 10.1016/S0140-6736(08)60954-X.
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Narcotic-Related Disorders
- Substance-Related Disorders
- Opioid-Related Disorders
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Opioid
- Narcotics
- Narcotic Antagonists
- Alcohol Deterrents
- Buprenorphine
- Naltrexone
Other Study ID Numbers
Other Study ID Numbers
- 0103012336
- R01DA014718-04 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.